OPKO Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) covers events occurring between May 26, 2009, and June 1, 2009. OPKO Health, Inc., a Delaware corporation, entered into material definitive agreements to raise capital through the sale of unregistered common stock to seven accredited investors.
Key Financial Metrics
The filing details a private placement transaction rather than operational financial results. Key metrics from this event include:
- Total Capital Raised: $31,000,000
- Shares Issued: 31,000,000 shares of Common Stock
- Price Per Share: $1.00
- Liquidity Impact: Immediate cash inflow of $31 million.
The filing text does not provide clear values for revenue, profit, operating margins, or existing debt levels.
Material Changes
The primary material change is the increase in outstanding share count by 31 million shares and the corresponding increase in cash assets. The transaction was executed via stock purchase agreements with seven specific investors, including Vector Group Ltd. and Chung Chia Company Limited.
Outlook, Risks, and Unusual Items
Transaction Terms: The shares issued are restricted securities, and no registration rights were granted to the investors. The issuance was exempt from registration requirements under Section 4(2) of the Securities Act of 1933 as it did not involve a public offering.
Related Party Transaction: Phillip Frost, M.D., the Company's Chairman and CEO, may be deemed to beneficially own 11.5% of Vector Group Ltd.'s outstanding stock, which invested $5,000,000 in the offering.
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the unregistered nature of the sale.
Investor Verification Checklist
- Verify the dilution impact of the 31 million new shares on existing shareholders.
- Confirm the beneficial ownership percentage of Phillip Frost, M.D., in Vector Group Ltd. to assess related party transaction implications.
- Review subsequent filings to determine how the $31 million capital raise was utilized (e.g., debt repayment, R&D, operations).
- Check for any registration rights granted in subsequent agreements, as none were granted in this specific filing.